KORU Medical chair receives 5,208-share stock award

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

KORU Medical Systems director R. John Fletcher received an equity grant of common stock. On the reported date, he was awarded 5,208 shares of KORU Medical Systems, Inc. common stock at an indicated value of $4.32 per share, reflecting compensation rather than an open-market purchase. Following this grant, he directly holds a total of 226,800 common shares, aligning his interests further with other shareholders.

Insider Trade Summary

Grant/Award: 5,208 shares

Grant/Award 1 txn

Insider FLETCHER R JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,208	$4.32	$22K

Holdings After Transaction: Common Stock — 226,800 shares (Direct)

Key Figures

Shares granted: 5,208 shares Grant price: $4.32 per share Total shares held after grant: 226,800 shares

3 metrics

Shares granted 5,208 shares Equity award of common stock

Grant price $4.32 per share Reported value for the stock grant

Total shares held after grant 226,800 shares Direct holdings following the transaction

Key Terms

Common Stock, Grant, award, or other acquisition, Form 4

3 terms

Common Stock financial

"He was awarded 5,208 shares of KORU Medical Systems, Inc. common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"The filing classifies it as a grant or other acquisition of 5,208 common shares"

Form 4 financial

"equity compensation is measured for disclosure in the insider transaction report on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KRMD director R. John Fletcher report?

R. John Fletcher reported receiving a grant of 5,208 shares of KORU Medical Systems common stock. The shares were valued at $4.32 each and represent equity compensation rather than an open-market purchase, aligning his financial incentives with long-term shareholder interests.

At what price was the KRMD stock grant to R. John Fletcher recorded?

The stock grant to R. John Fletcher was recorded at $4.32 per share. This price is used for reporting the value of the 5,208-share award and reflects how the equity compensation is measured for disclosure in the insider transaction report.

How many KORU Medical (KRMD) shares does R. John Fletcher hold after this grant?

After the reported grant, R. John Fletcher directly holds 226,800 shares of KORU Medical Systems common stock. This total includes the new 5,208-share award and shows his ongoing equity stake as Chairman of the Board and director of the company.

Was the KRMD insider transaction a market purchase or a share award?

The KRMD insider transaction was a share award, not a market purchase. The filing classifies it as a grant or other acquisition of 5,208 common shares, indicating compensation-based equity rather than an open-market buying decision by the reporting person.

What role does R. John Fletcher hold at KORU Medical Systems (KRMD)?

R. John Fletcher serves as Chairman of the Board and a director at KORU Medical Systems. His reported 5,208-share stock grant and resulting 226,800-share direct holding reflect equity compensation tied to his governance responsibilities and oversight role at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman of the Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		5,208	A	$4.32	226,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)